Evidence map›Paper›PMID 36507941›Full record

ArticleMolecular biotechnology2023

Investigation of the Potential Correlation Between RNA-Binding Proteins in the Evolutionarily Conserved MEX3 Family and Non-small-Cell Lung Cancer.

Ming Zhang, Linfeng Cao, Gouxin Hou, Xiaodong Lv, Jingjing Deng

Open access · hybridAbstract read
In one paragraph

Article in Molecular biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ming Zhang *Department of Pulmonary and Critical Care Medicine, The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, No. 1882 South Zhonghuan Road, Jiaxing, 314000, Zhejiang, People's Republic of China.
Linfeng Cao *Department of Pulmonary and Critical Care Medicine, The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, No. 1882 South Zhonghuan Road, Jiaxing, 314000, Zhejiang, People's Republic of China.
Gouxin HouDepartment of Oncology, The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Jiaxing, People's Republic of China.
Xiaodong LvDepartment of Pulmonary and Critical Care Medicine, The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, No. 1882 South Zhonghuan Road, Jiaxing, 314000, Zhejiang, People's Republic of China.
Jingjing DengDepartment of Pulmonary and Critical Care Medicine, The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, No. 1882 South Zhonghuan Road, Jiaxing, 314000, Zhejiang, People's Republic of China. djj910625@163.com.ORCID http://orcid.org/0000-0003-4233-3869
Jiaxing University · CN

Funding

Science Technology Project of Jiaxing 2020AD30044Science Technology Project of Jiaxing 2021AD30156the Key Discipline of Jiaxing Respiratory Medicine Construction Project no.2019-zc-04
6 · The paper itself

Abstract

Members of the MEX3 (muscle excess 3) family, uniquely characterised as mRNA binding proteins, play emerging roles in the post-transcriptional regulation of programmed biological processes, including tumour cell death and immune mechanisms, and have been shown to be involved in a variety of diseases. However, the role of MEX3 in non-small cell lung cancer (NSCLC) has not been fully elucidated. In this study, we found no significant changes in the sequence and copy number of the MEX3 gene through analysis using the COSMIC database, revealing its stability during malignancy development. Its expression in NSCLC was examined using the Oncomine™ database, and the prognosis of each member gene was analysed by Kaplan-Meier. The results showed that overexpression of MEX3A, MEX3B, MEX3C and MEX3D was associated with significantly worse OS in patients with LUAD, while overexpression of MEX3D was also associated with significantly worse OS in patients with LUSC. Afterwards, we applied the Tumour Immunology Estimation Resource (TIMER) tool to assess the correlation between different MEX3 and infiltrative immune cell infiltration. Ultimately, we found that most MEX3 members were highly expressed in NSCLC, with high expression suggesting poor prognosis and correlating with immune cell infiltration. The complexity and heterogeneity of NSCLC was understood through MEX3, setting the framework for the prognostic impact of MEX3 in NSCLC patients and the development of new targeted therapeutic strategies in the future.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansPhosphoproteinsRNA-Binding ProteinsRNA, MessengerMEX3A protein, humanMEX3B protein, humanPhosphoproteinsRNA-Binding ProteinsRNA, MessengerInvestigationMEX3 familyNon-small-cell lung cancerPotential correlationRNA-binding proteins

Identifiers

PMID36507941
PMCPMC10352443
OpenAlexW4311204645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.